Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prestige Consumer Healthcare (PBH) EBITDA (2016 - 2025)

Prestige Consumer Healthcare has reported EBITDA over the past 16 years, most recently at $48.1 million for Q4 2025.

  • Quarterly results put EBITDA at $48.1 million for Q4 2025, up 1.39% from a year ago — trailing twelve months through Dec 2025 was $196.4 million (down 2.9% YoY), and the annual figure for FY2025 was $211.4 million, up 2.44%.
  • EBITDA for Q4 2025 was $48.1 million at Prestige Consumer Healthcare, up from $42.9 million in the prior quarter.
  • Over the last five years, EBITDA for PBH hit a ceiling of $60.5 million in Q4 2023 and a floor of -$242.6 million in Q1 2023.
  • Median EBITDA over the past 5 years was $50.6 million (2021), compared with a mean of $35.3 million.
  • Biggest five-year swings in EBITDA: tumbled 531.25% in 2023 and later soared 117.93% in 2024.
  • Prestige Consumer Healthcare's EBITDA stood at $51.4 million in 2021, then grew by 14.57% to $58.9 million in 2022, then rose by 2.7% to $60.5 million in 2023, then dropped by 21.66% to $47.4 million in 2024, then grew by 1.39% to $48.1 million in 2025.
  • The last three reported values for EBITDA were $48.1 million (Q4 2025), $42.9 million (Q3 2025), and $52.9 million (Q2 2025) per Business Quant data.